Project Grant R21AI111097

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,000,000 to Taxis Pharmaceuticals Inc. to optimize lead oral drug candidates for treating multidrug-resistant Neisseria gonorrhoeae (NG) infections. The goal is to develop a narrow-spectrum oral therapeutic that can target drug-resistant NG strains, including those resistant to existing first-line antibiotics. The...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $299,999 to Planet Biotechnology Incorporated to develop a novel bispecific antibody for the prevention of gonorrhea. The project aims to engineer a fusion protein that combines elements of human antibodies with immune system components to broadly neutralize the causative bacteria, Neisseria gonorrhoeae, including...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $233,250 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Washington to develop and validate a rapid, point-of-care molecular test to detect Treponema pallidum antibiotic resistance. The key products to be delivered under this 2-year grant include: A multiplexed, point-of-care allele-specific loop-mediated isothermal amplification (AS-LAMP) assay to detect genetic markers of...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $802,798 to The Research Foundation For The State University Of New York to develop a novel class of antibiotics called Biamyxins (BMX) to target multidrug-resistant Gram-negative bacterial infections. The key products and services to be delivered include: Optimization of the lead BMX compound, HCC-0010, to...

This $195,480 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development and pilot implementation of a low-cost, point-of-care diagnostic assay to detect Neisseria gonorrhoeae infection and molecular markers of antimicrobial resistance in resource-limited settings. The award recipient, Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop new antimicrobial agents and combination therapies to combat the growing threat of Gram-negative bacterial pathogens, specifically carbapenem-resistant Acinetobacter baumannii (CRAB) and Klebsiella pneumoniae (CRKP). The $2,308,174 award, with a performance period from August 2024 to May 2029, will fund three...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $383,750 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Nebraska Medical Center (UNMC) to discover novel antimicrobial peptides that can effectively eliminate drug-resistant gram-negative bacteria. The project aims to elucidate the structure-activity relationship, toxicity, pharmacokinetics, and in vivo efficacy of a novel antimicrobial peptide called Verine...

This federal Project Grant award, valued at $243,361.00 and running from August 15, 2024 to July 31, 2026, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant is funding a project by Rush University Medical Center in Chicago, Illinois to establish workflows for rapid and inexpensive whole genome sequencing (WGS) of Neisseria gonorrhoeae (NG) directly from urine, throat, and rectal...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $229,411 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Northwestern University to investigate Neisseria gonorrhoeae double-stranded bacteriophage. The research aims to determine whether one or more phage islands can produce phage, explore the regulation of two essential LexA orthologs, and assess whether these phage(s) can infect Neisseria strains or species. This project builds upon the...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on developing small molecule inhibitors of the LPXH enzyme as novel antibiotics to treat multidrug-resistant Enterobacterales infections. The $747,763 award to Duke University will support the design, synthesis, and optimization of potent LPXH inhibitors with the goal of identifying a lead candidate with demonstrated...